Genomic BCR-ABL1 breakpoints in pediatric chronic myeloid leukemia
Genes, Chromosomes and Cancer, 08/10/2012
Krumbholz M et al. – Technical aspects of the highly sensitive DNA–based quantification of residual Chronic myeloid leukemia (CML) cells by specific fusion sequence during tyrosine kinase inhibitor therapy are exemplified in a subcohort of pediatric CML patients.



